Physician profile
Cory B Carter
NPI 1609188911
$2,504.25
in general payments reported to CMS, 2019-2025
43 companies · $584 in 2025
The $584 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $904 · 2020: $499 · 2021: $128 · 2022: $16.94 · 2023: $109 · 2024: $263 · 2025: $584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $771 · Consulting Fee: $150 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $770.99 |
| Consulting Fee | $150.00 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $358.66 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $181.19 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $150.00 | 2024 | Talvey |
| Astrazeneca Pharmaceuticals LP | $149.08 | 2019-2025 | Imfinzi, Enhertu |
| Celgene Corporation | $133.04 | 2019-2025 | Reblozyl |
| Daiichi Sankyo INC. | $132.26 | 2019-2025 | Enhertu |
| E.R. Squibb & Sons, L.L.C. | $125.92 | 2019-2025 | Opdualag, Opdivo |
| Pharmacyclics LLC, An Abbvie Company | $120.01 | 2019-2023 | Imbruvica |
| Astellas Pharma US INC | $100.35 | 2019-2025 | Vyloy |
| Genzyme Corporation | $99.89 | 2019-2023 | |
| Glaxosmithkline, LLC. | $86.39 | 2025 | Ojjaara, Jemperli, Zejula |
| Amgen INC. | $72.44 | 2019-2020 | |
| Array Biopharma INC | $69.51 | 2020-2025 | Xalkori, Mektovi, Braftovi |
| Abbvie INC. | $58.74 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.82 | 2019 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cory Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.